CompletedPhase 1

Buspirone for Opioid Tapering

United States18 participantsStarted 2018-05-30

Plain-language summary

This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces symptoms of opioid withdrawal among patients undergoing a clinically-indicated and supervised taper from their opioid pain medications. This is premised on strong preclinical scientific support but has not yet be well-examined in humans.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be at least 18 years old * Be undergoing taper of prescribed opioid pain medications at the study site Exclusion Criteria: * Being pregnant or breastfeeding * Past 7-day use of grapefruit juice or other strong Cytochrome (CYP) P450 inhibitors or inducers * Have medical or psychiatric condition that is contraindicated with buspirone administration * Current suicidality as assessed by clinic staff or the Columbia Suicide Severity Rating Scale

What they're measuring

Taper Completion

Timeframe: 28 days

Opioid Withdrawal Symptom Severity

Timeframe: 28 days

Trial details

NCT IDNCT03521960

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-06-30

View on ClinicalTrials.gov More Opioid-Related Disorders trials